Susceptibility to cervical cancer: An overview

Gynecologic Oncology

Volumn 126, Issue 2, 2012, Pages 304-311

  De Freitas, Antonio Carlos ^a   Gurgel, Ana Pavla Almeida Diniz ^a   Chagas, Bárbara Simas ^a   Coimbra, Eliane Campos ^a   Do Amaral, Carolina Maria Medeiros ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cervical cancer; Human Papillomavirus (HPV); Susceptibility to cervical cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MDM2; PROTEIN P53;

CANCER EPIDEMIOLOGY; CANCER SUSCEPTIBILITY; DNA POLYMORPHISM; DNA SEQUENCE; DNA VIRUS; DOWN REGULATION; GENETIC EPIDEMIOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 58; LIFESTYLE; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; WART VIRUS;

EID: 84862892092     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.047     Document Type: Review

References (136)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. J Clin 2011;61:69-90.
2. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996;1288(2):F55-78.
3. de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification of Papillomaviruses. Virology 2004;324(1):17-27. (Pubitemid 38737395)
4. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical Human Papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202(12):1789-99.
5. Hoory T, Monie A, Gravitt P, Wu T-C. Molecular epidemiology of Human Papillomavirus. J Formos Med Assoc 2008;107(3):198-217. (Pubitemid 351618642)
6. Bray F, Carstensen B, Møller H, Zappa M, Žakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14(9):2191-9. (Pubitemid 41603267)
7. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of Papillomavirus (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401(1):70-9.
8. Bravo IG, de Sanjosé S, Gottschling M. The clinical importance of understanding the evolution of Papillomaviruses. Trends Microbiol 2010;18:432-8.
9. Gnanamony M, Peedicayil A, Subhashini J, Ram TS, Rajasekar A, Gravitt P, et al. Detection and quantitation of HPV 16 and 18 in plasma of Indian women with cervical cancer. Gynecol Oncol 2010;116(3):447-51.
10. Ho C-M, Yang S-S, Chien T-Y, Huang S-H, Jeng C-J, Chang S-F. Detection and quantitation of Human Papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol Oncol 2005;99(3):615-21. (Pubitemid 41686545)
11. Kay P, Allan B, Denny L, Hoffman M, Williamson A-L. Detection of HPV 16 and HPV 18 DNA in the blood of patients with cervical cancer. J Med Virol 2005;75(3):435-9. (Pubitemid 40175910)
12. Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Shaji RV, et al. HPV DNA in plasma of patients with cervical carcinoma. J Clin Virol 2004;31(3):204-9. (Pubitemid 39311799)
13. Pornthanakasem W, Shotelersuk K, Termrungruanglert W, Voravud N, Niruthisard S, Mutirangura A. Human Papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer 2001;1(1):2.
14. Liu VW, Tsang P, Yip A, Ng TY, Wong LC, Ngan HY. Low incidence of HPV DNA in sera of pretreatment cervical cancer patients. Gynecol Oncol 2001;82(2): 269-72. (Pubitemid 32730602)
15. Kaspersen MD, Larsen PB, Ingerslev HJ, Fedder J, Petersen GB, Bonde J, et al. Identification of multiple HPV types on spermatozoa from human sperm donors. PLoS One 2011;6(3):e18095.
16. Weyn C, Thomas D, Jani J, Guizani M, Donner C, Van Rysselberge M, et al. Evidence of Human Papillomavirus in the placenta. J Infect Dis 2011;203(3): 341-3.
17. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2(5):342-50.
18. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human Papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128(4):927-35.
19. Pfister H. Chapter 8: Human Papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003;31:52-6.
20. Doorbar J. The Papillomavirus life cycle. J Clin Virol 2005;32:7-15.
21. Pittayakhajonwut D, Angeletti PC. Viral trans-factor independent replication of Human Papillomavirus genomes. Virol J 2010;7:123.
22. Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, et al. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011;10(1):140.
23. Steben M, Duarte-Franco E. Human Papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007;107(2 Suppl 1):S2-5. (Pubitemid 47559075)
24. Frazer I. Correlating immunity with protection for HPV infection. Int J Infect Dis 2007;11(Suppl. 2):S10-6. (Pubitemid 350298916)
25. Zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999;111(6):581-7.
26. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal Papillomavirus infection in young women. N Engl J Med 1998;338(7):423-8. (Pubitemid 28135669)
27. Frazer IH. Prevention of cervical cancer through Papillomavirus vaccination. Nat Rev Immunol 2004;4(1):46-54. (Pubitemid 38084131)
28. Lowy DR, Gillison ML. A new link between fanconi anemia and Human Papillomavirus-associated malignancies. J Natl Cancer Inst 2003;95(22): 1648-50. (Pubitemid 37509065)
29. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of Human Papillomavirus infection and vaccination-implications for second generation vaccines. Vaccine 2008;26(Supplement 10(0):K62-7.
30. Ronco LV, Karpova AY, Vidal M, Howley PM. Human Papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12(13):2061-72. (Pubitemid 28323879)
31. Barnard P, McMillan NA. The Human Papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999;259(2):305-13. (Pubitemid 29393381)
32. Bottley G,Watherston OG, Hiew Y-L, Norrild B, Cook GP, Blair GE. High-risk human Papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 2007;27(12):1794-9. (Pubitemid 351380256)
33. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, et al. TLR9 expression and function is abolished by the cervical cancer-associated Human Papillomavirus type 16. J Immunol 2007;178(5):3186-97. (Pubitemid 46333201)
34. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system. JAMA 2002;287(16):2114-9.
35. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, et al. The Johns Hopkins Medical Institutions B. Spontaneous regression of high-grade cervical dysplasia: effects of Human Papillomavirus type and HLA phenotype. Clin Cancer Res 2005;11(13):4717-23. (Pubitemid 41557190)
36. Wei Y-C, Chou Y-S, Chu T-Y. Detection and typing of minimal Human Papillomavirus DNA in plasma. Int J Gynaecol Obstet 2007;96(2):112-6. (Pubitemid 46399610)
37. Shimada T, Yamaguchi N, Nishida N, Yamasaki K, Miura K, Katamine S, et al. Human Papillomavirus DNA in plasma of patients with HPV16 DNA-positive uterine cervical cancer. Jpn J Clin Oncol 2010;40(5):420-4.
38. Dong SM, Pai SI, Rha S-H, Hildesheim A, Kurman RJ, Schwartz PE, et al. Detection and quantitation of Human Papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev 2002;11(1):3-6. (Pubitemid 34118306)
39. Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, Zheng Z-M. Could Human Papillomaviruses be spread through blood? J Clin Microbiol 2005;43(11): 5428-34. (Pubitemid 41612309)
40. Widschwendter A, Blassnig A, Wiedemair A, MÃller-Holzner E, MÃller HM, Marth C. Human Papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Lett 2003;202(2):231-9. (Pubitemid 37485896)
41. Rombaldi RL, Serafini EP, Mandelli J, Zimmermann E, Losquiavo KP. Perinatal transmission of Human Papilomavirus DNA. Virol J 2009;6:83.
42. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of Human Polyomaviruses and Papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 2002;53(4):263-76. (Pubitemid 35398497)
43. Shen Z-Y, Hu S-P, Lu L-C, Tang C-Z, Kuang Z-S, Zhong S-P, et al. Detection of Human Papillomavirus in esophageal carcinoma. J Med Virol 2002;68(3):412-6.
44. Gábor B, Imdahl A, György L, Pál O. HPV-infection in esophageal cancer as possible predictive factor after neoadjuvant therapy. Magy Seb 2006;59(2): 97-104.
45. Widschwendter A, Brunhuber T, Wiedemair A, Mueller-Holzner E, Marth C. Detection of Human Papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol 2004;31(4):292-7. (Pubitemid 39371063)
46. Bodaghi S, Yamanegi K, Xiao S-Y, Da Costa M, Palefsky JM, Zheng Z-M. Colorectal Papillomavirus infection in patients with colorectal cancer. Clin Cancer Res 2005;11(8):2862-7. (Pubitemid 40525184)
47. Klein F, Amin Kotb WFM, Petersen I. Incidence of Human Papilloma virus in lung cancer. Lung Cancer 2009;65(1):13-8.
48. Vink JM, van Kemenade FJ, Meijer CJLM, Casparie MK, Meijer GA, Boomsma DI. Cervix smear abnormalities: linking pathology data in female twins, their mothers and sisters. Eur J Hum Genet 2011;19(1):108-11.
49. Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev 2006;15(7):1413-4. (Pubitemid 44125303)
50. Magnusson PKE, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours. Int J Cancer 2000;88(5):698-701.
51. Couto E, Hemminki K. Heritable and environmental components in cervical tumors. Int J Cancer 2006;119(11):2699-701. (Pubitemid 44691327)
52. Ahlbom A, Lichtenstein P, Malmström H, Feychting M, Pedersen NL, Hemminki K. Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst 1997;89(4):287-93. (Pubitemid 27085890)
53. Alter BP. Cancer in fanconi anemia, 1927-2001. Cancer 2003;97(2):425-40. (Pubitemid 36133810)
54. Park JW, Pitot HC, Strati K, Spardy N, Duensing S, Grompe M, et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res 2010;70(23):9959-68.
55. Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, et al. Human Papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003;95(22):1718-21. (Pubitemid 37509080)
56. Hu W, Feng Z, Ma L, Wagner J, Rice JJ, Stolovitzky G, et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007;67(6):2757-65. (Pubitemid 46548964)
57. Bhattacharya P, Sengupta S. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. Gynecol Oncol 2005;99(1):176-82. (Pubitemid 41354599)
58. Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine doubleminute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell 2009;22(2):49-54.
59. Roh J-W, Kim BK, Lee CH, Kim J, Chung HH, Kim JW, et al. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res Featuring Preclinical Clin Cancer Ther 2010;18(9):453-9.
60. Roh J-W, Kim BK, Lee CH, Kim J, Chung HH, Kim JW, et al. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res 2010;18(9):453-9.
61. Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V, Ohnishi T. Polymorphism of the waf1 gene is related to susceptibility to cervical cancer in Japanese women. Int J Mol Med 2001;7(3):261-4.
62. Jiang P, Liu J, Li W, Zeng X, Tang J. Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women. Acta Biochim Biophys Sin (Shanghai) 2010;42(9):671-6.
63. Oliveira S, Sousa H, Santos AM, Pinto D, Pinto-Correia AL, Fontoura D, et al. The p53 r72p polymorphism does not influence cervical cancer development in a Portuguese population: a study in exfoliated cervical cells. J Med Virol 2008;80(3):424-9. (Pubitemid 351206891)
64. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. Tp53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 2009;10(8):772-84.
65. Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, et al. Tp53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev 2010;19(3):755-61.
66. Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis. Gynecol Oncol 2010;118(3):258-61.
67. de Vasconcellos Meissner R, Niskier Ferreira Barbosa R, VerÃssimo Fernandes J, Medeiros Galvão T, Oliveira Galvão AF, de Medeiros Oliveira GH. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev 2007;31(5):371-4. (Pubitemid 350176637)
68. Tian Q, Lu W, Chen H, Ye F, Xie X. The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. Int J Gynecol Cancer 2009;19:1011-4.
69. Chan PKS, Cheung T-H, Lin CK, Siu S-SN, Yim S-F, Lo KWK, et al. Association between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese. J Med Virol 2007;79(7):970-6. (Pubitemid 46871556)
70. Hildesheim A, Schiffman M, Scott DR, Marti D, Kissner T, Sherman ME, et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998;7(11): 1035-41. (Pubitemid 28514105)
71. Kanao H, Enomoto T, Ueda Y, Fujita M, Nakashima R, Ueno Y, et al. Correlation between p14 and p16 expression and HPV infection in uterine cervical cancer. Cancer Lett 2004;213(1):31-7. (Pubitemid 39118531)
72. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with Human Papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153(6):1741-8. (Pubitemid 28550662)
73. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16 as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92(2):276-84. (Pubitemid 32225381)
74. Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004;4(1):58.
75. Trimble CL, Genkinger JM, Burke AE, Hoffman SC, Helzlsouer KJ, Diener-West M, et al. Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol 2005;105(1):174-81. (Pubitemid 40189929)
76. Moktar A, Singh R, Vadhanam MV, Ravoori S, Lillard JW, Gairola CG, et al. Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int J Oncol 2011;39(4):941-7.
77. MacLaughlan SD, Lachance JA, Gjelsvik A. Correlation between smoking status and cervical cancer screening: a cross-sectional study. J Low Genit Tract Dis 2011;15(2):114-9.
78. Ward KK, Berenson AB, Breitkopf CR. Passive smoke exposure and abnormal cervical cytology in a predominantly Hispanic population. Am J Obstet Gynecol 2011;204(3):e1-6 213.
79. Ma YT, Collins SI, Young LS, Murray PG, Woodman CBJ. Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study. Br J Cancer 2011;104(9):1500-4.
80. Ghanem KG, Datta SD, Unger ER, Hagensee M, Shlay JC, Kerndt P, et al. The association of current hormonal contraceptive use with type-specific HPV detection. Sex Transm Infect 2011;87(5):385-8.
81. Au WW. Life style, environmental and genetic susceptibility to cervical cancer. Toxicology 2004;198(1-3):117-20. (Pubitemid 38609022)
82. Finan RR, Tamim H, Almawi WY. Identification of chlamydia trachomatis DNA in human papillomavirus (HPV) positive women with normal and abnormal cytology. Arch Gynecol Obstet 2002;266(3):168-71. (Pubitemid 36056615)
83. Baldez da Silva MFPT, Chagas BS, Guimarães V, Katz LMC, Felix PM, Miranda PM, et al. HPV31 and HPV33 incidence in cervical samples from women in Recife, Brazil. Genet Mol Res 2009;8(4):1437-43.
84. Soto-De Leon S, Camargo M, Sanchez R, Munoz M, Perez-Prados A, Purroy A, et al. Distribution patterns of infection with multiple types of Human Papillomaviruses and their association with risk factors. PLoS One 2011;6(2):e14705.
85. Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, et al. Human Papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis 2011;203(7):910-20.
86. Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, Herrero R, et al. Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst 2010;102(23):1794-804.
87. Cejtin HE. Gynecologic issues in the HIV-infected woman. Infect Dis Clin North Am 2008;22(4):709-39 [vii].
88. Sichero L, Villa LL. Epidemiological and functional implications of molecular variants of human papillomavirus. Braz J Med Biol Res 2006;39:707-17. (Pubitemid 43880927)
89. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007;120(8):1763-8. (Pubitemid 46399363)
90. Calleja-Macias IE, Kalantari M, Huh J, Ortiz-Lopez R, Rojas-Martinez A, Gonzalez- Guerrero JF, et al. Genomic diversity of Human Papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and native American variants. Virology 2004;319(2):315-23. (Pubitemid 38258283)
91. Junes-Gill K, Sichero L, Maciag PC, Mello W, Noronha V, Villa LL. Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil. J Med Virol 2008;80(9):1639-45.
92. López-Revilla R, Pineda MA, Ortiz-Valdez J, Sánchez-Garza M, Riego L. Human Papillomavirus type 16 variants in cervical intraepithelial neoplasia and invasive carcinoma in San Luis Potosí City, Mexico. Infect Agents Cancer 2009;4:3.
93. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al. Molecular variants of Human Papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81(Pt 12):2959-68. (Pubitemid 32000643)
94. del Refugio González-Losa M, Laviada Mier y Teran MA, Puerto-Solís M, García- Carrancá A. Molecular variants of HPV type 16 e6 among Mexican women with LSIL and invasive cancer. J Clin Virol 2004;29(2):95-8.
95. Berumen J. Nuevos virus del papiloma humano descubiertos en México y su asociación a la alta incidencia del cáncer de cérvix. Gac Med Mex 2003;139: S3-9.
96. Bernard H-U, Calleja-Macias IE, Dunn ST. Genome variation of Human Papillomavirus types: phylogenetic and medical implications. Int J Cancer 2006;118(5):1071-6. (Pubitemid 43185592)
97. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al. Human Papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997;71(3):2463-72. (Pubitemid 27078630)
98. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, et al. Evolution of Human Papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993;67(11):6424-31. (Pubitemid 23309106)
99. Arias-Pulido H, Peyton CL, Torrez-Martínez N, Anderson DN, Wheeler CM. Human Papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology 2005;338(1):22-34. (Pubitemid 40835923)
100. Bernard H-U. The clinical importance of the nomenclature, evolution and taxonomy of Human Papillomaviruses. J Clin Virol 2005;32(Suppl. 1):S1-6. (Pubitemid 40332583)
101. Raiol T, Wyant PS, de Amorim RMS, Cerqueira DM, Milanezi N von G, Brígido M de M, et al. Genetic variability and phylogeny of the high-risk HPV-31, -33, -35, - 52, and -58 in Central Brazil. J Med Virol 2009;81(4):685-92.
102. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self-assembly of Human Papillomavirus type 16 L1 and L1- into virus-like particles. J Virol 1993;67(12):6929-36. (Pubitemid 23343814)
103. Touze A, El Mehdaoui S, Sizaret P-Y, Mougin C, Munoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16-variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 1998;36(7):2046-51. (Pubitemid 28277800)
104. Pande S, Jain N, Prusty BK, Bhambhani S, Gupta S, Sharma R, et al. Human Papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J Clin Microbiol 2008;46(3):1060-6. (Pubitemid 351380001)
105. Wu Y, Chen Y, Li L, Yu G, He Y, Zhang Y. Analysis of mutations in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China. J Gen Virol 2006;87(5):1181-8.
106. Kast W, Brandt R, Sidney J, Drijfhout J, Kubo R, Grey H, et al. Role of HLA motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152(8):3904-12. (Pubitemid 24111062)
107. Londesborough P,Ho L, Terry G, Cuzick J,Wheeler C, Singer A.Human Papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69(5):364-8. (Pubitemid 26384104)
108. Zehbe I, Wilander E, Delius H, Tommasino M. Human Papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 1998;58(4):829-33. (Pubitemid 28099499)
109. Kämmer C, Tommasino M, Syrjänen S, Delius H, Hebling U, Warthorst U, et al. Variants of the long control region and the E6 oncogene in European Human Papillomavirus type 16 isolates: implications for cervical disease. Br J Cancer 2002;86(2):269-73. (Pubitemid 34185157)
110. Zehbe I, Lichtig H, Westerback A, Lambert PF, Tommasino M, Sherman L. Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential. Mol Cancer 2011;10:77.
111. Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett 2000;156(2):159-65. (Pubitemid 30394673)
112. Hu X, Pang T, Guo Z, Mazurenko N, Kisseljov F, Pontén J, et al. HPV16 E6 gene variations in invasive cervical squamous cell carcinoma and cancer in situ from Russian patients. Br J Cancer 2001;84(6):791-5. (Pubitemid 32275652)
113. Cai HB, Chen CC, Ding XH. Human Papillomavirus type 16 E6 gene variations in Chinese population. Eur J Surg Oncol 2010;36(2):160-3.
114. Choi B-S, Kim SS, Yun H, Jang DH, Lee J-S. Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers. J Med Virol 2007;79(4):426-30. (Pubitemid 46355443)
115. Song S-H, Lee J-K, Seok O-S, Saw H-S. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix. Gynecol Oncol 2007;104(3):732-8. (Pubitemid 46240268)
116. Tornesello ML, Duraturo ML, Salatiello I, Buonaguro L, Losito S, Botti G, et al. Analysis of Human Papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol 2004;74(1):117-26. (Pubitemid 38988868)
117. van Duin M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, et al. Analysis of Human Papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 2000;81(Pt 2):317-25. (Pubitemid 30077274)
118. Giannoudis A, van DuinM, Snijders PJF, Herrington CS. Variation in the E2-binding domain of HPV 16 is associatedwith high-grade squamous intraepithelial lesions of the cervix. Br J Cancer 2001;84(8):1058-63. (Pubitemid 32448502)
119. Bhattacharjee B, Sengupta S. Hpv16 E2 gene disruption and polymorphisms of E2 and LCR: some significant associations with cervical cancer in Indian women. Gynecol Oncol 2006;100(2):372-8. (Pubitemid 43075272)
120. Shang Q, Wang Y, Fang Y, Wei L, Chen S, Sun Y, et al. Human Papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in identification of cervical carcinomas in patients in Northeast China. J Clin Microbiol 2011;49(7):2656-63.
121. Schmidt M, Kedzia W, Goździcka-Józefiak A. Intratype HPV16 sequence variation within LCR of isolates from asymptomatic carriers and cervical cancers. J Clin Virol 2001;23(1-2):65-77. (Pubitemid 32930101)
122. Dong XP, Pfister H. Overlapping YY1- and aberrant SP1-binding sites proximal to the early promoter of human papillomavirus type 16. J Gen Virol 1999;80(Pt 8): 2097-101. (Pubitemid 29389147)
123. Hecht JL, Kadish AS, Jiang G, Burk RD. Genetic characterization of the Human Papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer 1995;60(3): 369-76.
124. De Boer MA, Peters LAW, Aziz MF, Siregar B, Cornain S, Vrede MA, et al. Human Papillomavirus type 18 variants: histopathology and E6/E7 polymorphisms in three countries. Int J Cancer 2005;114(3):422-5. (Pubitemid 40279963)
125. Cerqueira DM, Raiol T, Véras NMC, Gal Milanezi N, Amaral FA, Macedo Brígido M, et al. New variants of Human Papillomavirus type 18 identified in Central Brazil. Virus Genes 2008;37:282-7.
126. De la Cruz-Hernández E, García-Carrancá A, Mohar-Betancourt A, Dueñas- González A, Contreras-Paredes A, Pérez-Cardenas E, et al. Differential splicing of E6 within Human Papillomavirus type 18 variants and functional consequences. J Gen Virol 2005;86(9):2459-68.
127. Halpen A, McBride A, Myers G, Baker C, Wheeler CM, Doobar J. Human papillomaviruses. a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Los Alamos National laboratory; 1997.
128. Cerqueira DM, Raiol T, Véras NMC, Von Gal Milanezi N, Amaral FA, De Macedo Brígido M, et al. New variants of human papillomavirus type 18 identified in Central Brazil. Virus Genes 2008;37(2):282-7.
129. Combita A-L, Touze A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of Human Papillomaviruses. J Virol 2002;76(13):6480-6. (Pubitemid 34633513)
130. Rose BR, Thompson CH, Zhang J, Stoeter M, Stephen A, Pfister H, et al. Sequence variation in the upstream regulatory region of HPV 18 isolates from cervical cancers. Gynecol Oncol 1997;66(2):282-9. (Pubitemid 27335418)
131. de Boer MA, Peters LAW, Aziz MF, Siregar B, Cornain S, Vrede MA, et al. Human Papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and the Netherlands. Gynecol Oncol 2004;94(2):488-94. (Pubitemid 39024558)
132. Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, Allan B, Williamson A-L, et al. Worldwide genomic diversity of the high-risk Human Papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol 2005;79(21):13630-40. (Pubitemid 41508175)
133. Comerford SA, McCance DJ, Dougan G, Tite JP. Identification of T- and B-cell epitopes of the E7 protein of Human Papillomavirus type 16. J Virol 1991;65(9): 4681-90.
134. Cento V, Rahmatalla N, Ciccozzi M, Perno CF, Ciotti M. Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology. J Med Virol 2011;83(10):1752-61.
135. Xin CY, Matsumoto K, Yoshikawa H, Yasugi T, Onda T, Nakagawa S, et al. Analysis of E6 variants of Human Papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. Cancer Lett 2001;170(1):19-24. (Pubitemid 32607656)
136. Vrtačnik Bokal E, Kocjan BJ, Poljak M, Bogovac Ž, Jančar N. Genomic variants of Human Papillomavirus genotypes 16, 18, and 33 in women with cervical cancer in Slovenia. J Obstet Gynaecol Res 2010;36(6):1204-13.